Abelacimab for Prevention of Venous Thromboembolism

Prof.  Jeffrey Weitz, President of ISTH presented a late-breaking abstract about the medicine Abelacimab.

The QUAZAR AML-001 Maintenance Trial

Prof. Eytan Stein talked about maintenance therapy for acute myeloid leukemia.

Idecabtagene vicleucel, a BCMA-​directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma

Prof. Oriol speaks about the updated results of KarMMa trial.

Novelties in the treatment of Multiple Myeloma

Prof. Ocio give us a brief overview about the main messages of the studies presented on EHA 2021 regarding multiple myeloma.

Treatment of hematological malignancies in 2021

Prof. Corradini speaks about the advance of CAR T-cell therapies and T-cell engaging antibodies.

Novelties in the treatment of chronic myeloid leukemia

Prof. Saglio speaks about the latest news came out from the EHA meeting in the field of CML treatment.

Novelties in the treatment of follicular lymphoma

Prof. Hübel speaks about the latest news came out from the EHA meeting in the field of follicular lymphoma treatment.

Harnessing the immune system in multiple myeloma: CAR T-cell therapy and bispecific antibodies

Prof. Leleu  speaks about the clinical and practical aspects of the topic.

Results from the JAKARTA and JAKARTA2 trials

Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis therapy and after prior ruxolitinib.

Novelties on the treatment of Multiple Myeloma

Prof. Mohty shares with us his personal thought in the recent advances in multiple myeloma.

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

The open-label, international, randomized, phase 3 KEYNOTE-204 (NCT02684292) study showed that in pts with R/R cHL, the PD-1 inhibitor pembro was superior to BV and demonstrated statistically significant, clinically meaningful improvement in PFS, with safety consistent with previous reports. This post hoc exploratory analysis of KEYNOTE-204 evaluated pembro vs BV by number of prior lines of therapy. https://ashpublications.org/blood/article/136/Supplement%201/12/470837/Effect-of-Pembrolizumab-Pembro-Monotherapy-Versus

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Several clinical factors have been proposed to predict successful tyrosine kinase inhibitor (TKI) discontinuation for treatment-free remission (TFR), among which a longer duration of total TKI or deep molecular response (DMR) duration correlate with increased success of TFR. Although many guidelines have been proposed to safely select patients who would be candidates for TFR attempt, there is some discrepancy regarding which duration of DMR and/or Imatinib (IM) treatment optimally stratifies patients according to their probability of TFR success. These suggested DMR or IM treatment durations are often the result of a panel consensus, and the method of calculation of these thresholds as categorical values is not provided. Thus, there is a practical need for an evidence-based determination of duration of IM therapy while awaiting TFR attempt to establish if the likelihood of successful TKI discontinuation reaches an optimal maximum after a certain duration of treatment and/or DMR. The present study attempted to define the optimal (i.e. shortest) duration of IM treatment or DMR that predicts TFR success at a specified level of confidence. https://ashpublications.org/blood/article/136/Supplement%201/54/471081/Optimal-Duration-of-Imatinib-Treatment-Deep

Novelties on the treatment of Multiple Myeloma and Plasma Cell Disorders

The key finding that we have learned about multiple myeloma on ASH 2020. About frontline therapy, early relapse therapy and late relapse therapy.  - GRIFFIN trial  - FORTE trial  - APOLLO trial  - CAR T-Cell Therapies  - Bispecific drugs

Comprehensive summary of novel multiple myeloma data from ASH2020

Summarized studies: Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial https://ash.confex.com/ash/2020/webprogram/Paper136907.html Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial https://pubmed.ncbi.nlm.nih.gov/32325490/ Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: The Phase 3 Maia Study https://ash.confex.com/ash/2020/webprogram/Paper134847.html Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial https://pubmed.ncbi.nlm.nih.gov/31836199/ Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial https://ash.confex.com/ash/2020/webprogram/Paper134538.html The Phase 3 TOURMALINE-MM2 Trial: Oral Ixazomib, Lenalidomide, and Dexamethasone Vs Placebo-Rd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma https://ash.confex.com/ash/2020/webprogram/Paper137007.html Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone Versus Pomalidomide and Dexamethasone Alone in Patients  with Relapsed/Refractory Multiple Myeloma (RRMM) https://ash.confex.com/ash/2020/webprogram/Paper135874.html Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study https://ash.confex.com/ash/2020/webprogram/Paper141029.html BCMA Targeted Therapies updates CAR T-cell Therapies updates Part 1 Results of a Dose Finding Study of Belantamab Mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) https://ash.confex.com/ash/2020/webprogram/Paper134836.html

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

FMS-like receptor tyrosine kinase-3 (FLT3) mutations are common in acute myeloid leukemia (AML) and are associated with poor prognosis. Historically, patients with relapsed/refractory (R/R) FLT3 mutation–positive (FLT3mut+) AML experienced dismal survival outcomes. Gilteritinib, a highly potent and selective FLT3 inhibitor, was recently approved as the first targeted therapy for patients with R/R FLT3mut+ AML, and has the potential to bring significant clinical benefits to these patients. The randomized, phase 3 ADMIRAL trial (NCT02421939; Perl, et al. 2019) was the first head-to-head study that evaluated 120-mg/day gilteritinib versus salvage chemotherapy in R/R FLT3mut+ AML patients. The ADMIRAL trial demonstrated that gilteritinib was superior to salvage chemotherapy based on significantly longer median overall survival (OS) and higher response rates, including complete remission/complete remission with partial hematological recovery (CR/CRh), composite CR (CRc), and hematopoietic stem cell transplantation (HSCT) rate. Based on these results, the current study estimated the number needed to treat (NNT) with gilteritinib, compared with salvage chemotherapy, in order to evaluate its clinical benefit with CR/CRh, CRc, 1-year OS, and HSCT rates. https://ash.confex.com/ash/2020/webprogram/Paper136184.html

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Polatuzumab vedotin (Pola) combined with rituximab (R) demonstrated activity and tolerability in a Phase (Ph) II trial of patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (Morschhauser et al. Lancet 2019). The pro-survival MCL-1 protein has been identified as a mechanism of resistance to venetoclax (Ven), a potent inhibitor of BCL-2, in non-Hodgkin lymphoma cell lines. Preclinical studies have demonstrated that concurrent treatment with Pola promotes MCL-1 degradation and enhances anti-tumor efficacy in vivo, thus providing a strong rationale for the combination with Ven (Amin et al. AACR 2020). We sought to determine whether the combination of Pola-Ven-R might further enhance anti-tumor response. Here, we present the primary efficacy and safety analysis from a Ph Ib/II study of Pola-Ven-R in pts with R/R DLBCL (GO29833; NCT02611323). https://ashpublications.org/blood/article/136/Supplement%201/45/470363/Polatuzumab-Vedotin-Plus-Venetoclax-with-Rituximab

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Best of ASH

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)